Search Results - "Murray, Nigel P."

Intravascular Lymphoma Presenting as Multiple Endocrine Failure, Transforming Into the Hemophagocytic Variant, and Relapsing as a Thrombotic Microangiopathy.

Authors: Murray, Nigel P. Escobar, Cinthia Ramos, Enrique et al.

Source: Case Reports in Hematology. 9/17/2025, Vol. 2025, p1-7. 7p.

Minimal Residual Disease in Breast Cancer: Tumour Microenvironment Interactions, Detection Methods and Therapeutic Approaches.

Authors: Murray, Nigel P. Aedo, Socrates

Source: International Journal of Molecular Sciences. Dec2025, Vol. 26 Issue 23, p11346. 30p.

The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.

Authors: Murray, Nigel P. Fuentealba, Cynthia Reyes, Eduardo et al.

Source: Turkish Journal of Urology. Sep2020, Vol. 46 Issue 5, p360-366. 7p.

The role of matrix metalloproteinase-2 in the metastatic cascade: a review.

Authors: Murray, Nigel P.^1,2 nigelpetermurray@gmail.com

Source: Oncologie (De Gruyter). Jan2024, Vol. 26 Issue 1, p27-40. 14p.

Managing a Burning Face: Clinical Manifestations and Therapeutic Approaches for Neurogenic Rosacea.

Authors: Aedo, Gabriel Chahuán, Marco Gatica, Elsa et al.

Source: International Journal of Molecular Sciences. Mar2025, Vol. 26 Issue 5, p2366. 16p.

The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.

Authors: Murray, Nigel P. Aedo, Socrates Fuentealba, Cynthia et al.

Source: Ecancermedicalscience. 2020, Vol. 14 Issue 1063-1111, p1-16. 16p.

The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer.

Authors: Murray, Nigel P. Reyes, Eduardo Salazar, Anibal et al.

Source: Turkish Journal of Urology. May2020, Vol. 46 Issue 3, p186-195. 10p.

Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.

Authors: Murray, Nigel P. Aedo, Socrates Fuentealba, Cynthia et al.

Source: Urology Journal. May/Jun2020, Vol. 17 Issue 3, p262-270. 9p.

Platelet-to-lymphocyte ratio and systemic immune-inflammation index versus circulating prostate cells to predict significant prostate cancer at first biopsy.

Authors: Murray, Nigel P. Fuentealba, Cynthia Salazar, Aníbal et al.

Source: Turkish Journal of Urology. Mar2020, Vol. 46 Issue 2, p115-122. 8p.

Common B-cell acute lymphoblastic leukaemia in a 70-year-old woman presenting 2 years after carboplatin-taxane radiotherapy for endometrial cancer.

Authors: Murray, Nigel P. Orrego, Shenda Antonio López, Marco et al.

Source: Ecancermedicalscience. 2019, Vol. 13 Issue 962-995, p1-7. 7p.

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.

Authors: Murray, Nigel P. Aedo, Sócrates Villalon, Ricardo et al.

Source: Ecancermedicalscience. 2019, Issue 935-961, p1-11. 11p.

Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.

Authors: Murray, Nigel P. Aedo, Socrates Fuentealba, Cynthia et al.

Source: Ecancermedicalscience. 2019, Issue 911-934, p1-15. 15p.

Transitory Spontaneous Remission of Myelodysplasia in an Elderly Man while Receiving Intravesical Bacillus Calmette-Guérin for Bladder Cancer: A Case Report and Review of the Literature.

Authors: Murray, Nigel P. Fuentealba, Cynthia Salazar, Isidora et al.

Source: Case Reports in Hematology. 11/11/2018, p1-7. 7p.

Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review.

Authors: Murray, Nigel P. Muñoz, Lorena Minzer, Simona et al.

Source: Case Reports in Hematology. 9/5/2018, p1-4. 4p.

The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy.

Authors: Murray, Nigel P. Aedo, Socrates Fuentealba, Cynthia et al.

Source: Ecancermedicalscience. 2018, Vol. 12 Issue 844-874, p1-11. 11p.

How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome.

Authors: Murray, Nigel P. Aedo, Socrates Fuentealba, Cynthia et al.

Source: Turkish Journal of Urology. Dec2017, Vol. 43 Issue 4, p456-461. 6p.

CD19 ⁽⁺⁾ CD56 ^(-) myeloma arising in a patient who failed two courses of immunosupressive therapy for aplastic anaemia.

Authors: Murray, Nigel P. Ruiz, M. Amparo Miranda, G. Maximiliano

Source: Ecancermedicalscience. 2017, Vol. 11 Issue 709-727, p1-7. 7p.

The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance.

Authors: Murray, Nigel P. Reyes, Eduardo Fuentealba, Cynthia et al.

Source: Ecancermedicalscience. 2017, Vol. 11 Issue 709-727, p1-7. 7p.

Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.

Authors: Murray, Nigel P. Aedo, Sócrates Reyes, Eduardo et al.

Source: Ecancermedicalscience. 2016, Vol. 10 Issue 651-673, p1-8. 8p.

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men.

Authors: Murray, Nigel P. Reyes, Eduardo Orellana, Nelson et al.

Source: BioMed Research International. 2014, Vol. 2014, p1-8. 8p.